Eric Kuo, MD
Hematology & Oncology · San Mateo, CANPI 1962907014
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (52.6%), speaking fees and education — rather than concentrated in one kind of arrangement. 35 manufacturers reported payments, led by Corcept Therapeutics at 48.5% of the total.
Across 92 payments — averaging $53.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Corcept Therapeutics$2K
- Novartis$222
- E.r. Squibb & Sons, L.L.C.$186
- AstraZeneca$173
- Johnson & Johnson$155
- Gilead$135
- plus $2K from 29 others
What the payments were for
- Speaking & faculty fees$2,20045%
- Travel & lodging$481%
- Food & beverage$2,58053%
- Education$792%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Corcept Therapeutics | 4 | $2,378 |
| Novartis | 7 | $222 |
| E.r. Squibb & Sons, L.L.C. | 9 | $186 |
| AstraZeneca | 6 | $173 |
| Johnson & Johnson | 5 | $155 |
| Gilead(2 entities) | 6 | $135 |
| Daiichi Sankyo Inc. | 5 | $131 |
| Agios Pharmaceuticals, Inc. | 4 | $129 |
| Bristol Myers Squibb | 3 | $126 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $96 |
| Merck | 3 | $84 |
| Seagen Inc. | 1 | $79 |
| Regeneron Healthcare Solutions, Inc. | 2 | $77 |
| Incyte Corporation | 3 | $74 |
| ADC Therapeutics America, Inc. | 2 | $74 |
| Astellas Pharma US Inc | 3 | $73 |
| Novocure Inc. | 3 | $65 |
| Geron Corporation | 2 | $62 |
| Pfizer | 2 | $53 |
| GSK | 2 | $50 |
| Rigel Pharmaceuticals, Inc. | 2 | $47 |
| Taiho Oncology, Inc. | 1 | $45 |
| Caris MPI, Inc. | 2 | $45 |
| Jazz Pharmaceuticals Inc. | 1 | $39 |
| AbbVie | 1 | $34 |
| Sanofi | 1 | $33 |
| Lilly USA, LLC | 1 | $33 |
| Beone Medicines USA, Inc. | 1 | $30 |
| Array Biopharma Inc | 1 | $30 |
| Adaptive Biotechnologies Corporation | 1 | $30 |
| Tempus AI, Inc | 1 | $28 |
| Puma Biotechnology, Inc. | 1 | $26 |
| Bayer | 1 | $22 |
| Aadi Bioscience, Inc. | 1 | $21 |
| Surmodics, Inc. | 1 | $21 |
How this compares
$4,907 in reported general payments places this provider in the 55th percentile of 1,363 hematology & oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in San Mateo
- Dennis SlamonLos Angeles$3.1M
- Sandra HorningStanford$2.5M
- Mohammadbagher ZiariCorona$2.5M
- George YaghmourLos Angeles$1.9M
- Robert VescioWest Hollywood$1.1M
- Kevin KellyLos Angeles$894K
- Johnny ChangEncino$884K
- Nitin RohatgiSacramento$814K
- Omid HamidSanta Monica$809K
- Catherine CoombsOrange$786K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.